A. Jaeger
Research Subjects
A. Jaeger has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
A. Sarrazin
Owkin, Paris, France
2 shared publications- Aurélie Kamoun
Cartes d'Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France
2 shared publications - Barbara Pistilli
Department of Medical Oncology, Gustave Roussy, Villejuif, France
2 shared publications - Benoit Schmauch
Owkin, Paris, France
2 shared publications - Charlie Saillard
Owkin, Paris, France
2 shared publications - Damien Drubay
Gustave Roussy, Villejuif, France
2 shared publications
Latest Publications
- Open Access
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slides
Accurate risk stratification is critical for guiding treatment decisions in early breast cancer. We present an artificial intelligence (AI)-based tool that analyzes digitized tumor slides to predict 5-year metastasis-free survival (MFS) in patients with estrogen receptor-positive, HER2-negative (ER + /HER2 − ) early breast cancer (EBC). Our deep learning model, RlapsRisk BC, independently predicts MFS and provides significant prognostic value beyond traditional clinico-pathological variables (C-index 0.81 vs 0.76, p < 0.05). Applying a 5% MFS event probability threshold stratifies patients into low- and high-risk groups. After dichotomization, combining RlapsRisk BC with clinico-pathological factors increases cumulative sensitivity (0.69 vs 0.63) and dynamic specificity (0.80 vs 0.76) compared to clinical factors alone. Expert analysis of high-impact regions identified by the model highlights well-established morphological features, supporting its interpretability and biological relevance.
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Open AccessDeep learning assessment of metastatic relapse risk from digitized breast cancer histological slides
Accurate risk stratification is critical for guiding treatment decisions in early breast cancer. We present an artificial intelligence (AI)-based tool that analyzes digitized tumor slides to predict 5-year metastasis-free survival (MFS) in patients with estrogen receptor-positive, HER2-negative (ER + /HER2 − ) early breast cancer (EBC). Our deep learning model, RlapsRisk BC, independently predicts MFS and provides significant prognostic value beyond traditional clinico-pathological variables (C-index 0.81 vs 0.76, p < 0.05). Applying a 5% MFS event probability threshold stratifies patients into low- and high-risk groups. After dichotomization, combining RlapsRisk BC with clinico-pathological factors increases cumulative sensitivity (0.69 vs 0.63) and dynamic specificity (0.80 vs 0.76) compared to clinical factors alone. Expert analysis of high-impact regions identified by the model highlights well-established morphological features, supporting its interpretability and biological relevance.
- Open Access
Deep Learning Allows Assessment of Risk of Metastatic Relapse from Invasive Breast Cancer Histological Slides
Background Correctly classifying early estrogen receptor-positive and HER2-negative (ER+/HER2) breast cancer (EBC) cases allows to propose an adapted adjuvant systemic treatment strategy. We developed a new AI-based tool to assess the risk of distant relapse at 5 years for ER+/HER2− EBC patients from pathological slides. Patients and Methods The discovery dataset (GrandTMA) included 1429 ER+/HER2− EBC patients, with long-term follow-up and an available hematoxylin-eosin and saffron (HES) whole slide image (WSI). A Deep Learning (DL) network was trained to predict metastasis free survival (MFS) at five years, based on the HES WSI only (termed RlapsRisk). A combined score was then built using RlapsRisk and well established prognostic factors. A threshold corresponding to a probability of MFS event of 5% at 5 years was applied to dichotomize patients into low or high-risk groups. The external validation, as well as assessment of the additional prognosis value of the DL model beyond standard clinico-pathologic factors were carried out on an independent, prospective cohort (CANTO, NCT01993498) including 889 HES WSI of ER+/HER2− EBC patients. Results RlapsRisk was an independent prognostic factor of MFS in multivariable analysis adjusted for established clinico-pathological factors (pConclusions Our deep learning model developed on digitized HES slides provided additional prognostic information as compared to current clinico-pathological factors and has the potential of valuably informing the decision making process in the adjuvant setting when combined with current clinico-pathological factors.
Open AccessDeep Learning Allows Assessment of Risk of Metastatic Relapse from Invasive Breast Cancer Histological Slides
Background Correctly classifying early estrogen receptor-positive and HER2-negative (ER+/HER2) breast cancer (EBC) cases allows to propose an adapted adjuvant systemic treatment strategy. We developed a new AI-based tool to assess the risk of distant relapse at 5 years for ER+/HER2− EBC patients from pathological slides. Patients and Methods The discovery dataset (GrandTMA) included 1429 ER+/HER2− EBC patients, with long-term follow-up and an available hematoxylin-eosin and saffron (HES) whole slide image (WSI). A Deep Learning (DL) network was trained to predict metastasis free survival (MFS) at five years, based on the HES WSI only (termed RlapsRisk). A combined score was then built using RlapsRisk and well established prognostic factors. A threshold corresponding to a probability of MFS event of 5% at 5 years was applied to dichotomize patients into low or high-risk groups. The external validation, as well as assessment of the additional prognosis value of the DL model beyond standard clinico-pathologic factors were carried out on an independent, prospective cohort (CANTO, NCT01993498) including 889 HES WSI of ER+/HER2− EBC patients. Results RlapsRisk was an independent prognostic factor of MFS in multivariable analysis adjusted for established clinico-pathological factors (pConclusions Our deep learning model developed on digitized HES slides provided additional prognostic information as compared to current clinico-pathological factors and has the potential of valuably informing the decision making process in the adjuvant setting when combined with current clinico-pathological factors.